A
Aratana Therapeutics
Develops and markets innovative therapeutics for pets
About Aratana Therapeutics
Aratana Therapeutics, now part of Elanco, specializes in developing and commercializing innovative therapeutics for pets. The company focuses on providing solutions that improve the health and quality of life for companion animals, including dogs and cats. Aratana operates in the animal health market, serving veterinarians and pet owners who seek advanced treatments for their pets. The business model revolves around the research, development, and commercialization of veterinary pharmaceuticals, which are sold through veterinary clinics and pet hospitals. Revenue is generated primarily through the sale of these therapeutic products. Aratana's portfolio includes treatments for pain management, cancer, and other chronic conditions in pets. The company leverages its expertise in veterinary medicine to address unmet medical needs in the pet care industry.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2013
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 28.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Veterinary, Biotechnology, Oncology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Jan 2014
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2019 | $0 | — | Elanco | ↗ |
| POST IPO EQUITY✓Other financing | Mar 2018 | $12M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Aratana Therapeutics is 100 monthly website visits, down 33.3% over the last three months. Aratana Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Okapi SciencesLeuven, BelgiumAntiviral drug development platform for veterinary applications
$37Mvaluation
VT
Vet TherapeuticsLouisville, United StatesVet Therapeutics is developing antibody-based therapies to treat pet cancer and chronic conditions
→
Aratana Therapeutics in the Leawood ecosystem
The Aratana Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
MPM BioImpact
Avalon Ventures
Series B and later3 investors entered at this stage
Kansas Bioscience Authority- MAMidwest Venture Alliance
Middleland Capital
Other known investors5 additional known investors
Elanco
KU Leuven
Cultivian Sandbox Ventures
Gemma Frisius Fund - GFF
Women's Capital Connection
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aratana Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aratana Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










